Aliskiren reduced renal fibrosis in mice with chronic ischemic kidney injurybeyond the direct renin inhibition

Hypertension Research

Volumn 35, Issue 3, 2012, Pages 304-311

  Sun, Chiao Yin ^a,b   Cherng, Wen Jin ^a,b   Jian, Hui Zhen ^a,b   Hsu, Hsiang Hao ^a,b   Wu, I Wen ^a,b   Hsu, Heng Jung ^a,b   Wu, Mai Szu ^a,b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

chronic renal ischemia; direct renin inhibitor; renal fibrosis; renin angiotensin aldosterone system

Indexed keywords

ALISKIREN; CASPASE 3; COLLAGEN TYPE 1; KLOTHO PROTEIN; PRORENIN RECEPTOR; PROTEIN BAX; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; IMMUNOFLUORESCENCE TEST; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; MOUSE; NEPHROSCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; CASPASE 3; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; FUMARATES; GLUCURONIDASE; ISCHEMIA; KIDNEY; KIDNEY FAILURE, CHRONIC; MICE; MICE, INBRED STRAINS; RENAL ARTERY; RENIN; SURGICAL INSTRUMENTS;

EID: 84857943830     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.181     Document Type: Article

References (37)

1. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644-2648. (Pubitemid 47531190)
2. Yang WC, Hwang SJ. Incidence, prevalence and mortality trends of dialysis end-stage renal disease in Taiwan from 1990 to 2001: the impact of national health insurance. Nephrol Dial Transplant 2008; 23: 3977-3982.
3. Levin A, Djurdjev O, Beaulieu M, Er L. Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort. Am J Kidney Dis 2008; 52: 661-671.
4. Masuo K, Lambert GW, Esler MD, Rakugi H, Ogihara T, Schlaich MP. The role of sympathetic nervous activity in renal injury and end-stage renal disease. Hypertens Res 2010; 33: 521-528.
5. Preston RA, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365-1377. (Pubitemid 28039562)
6. Lee CC, Sun CY, Wu MS. Long-term modality-related mortality analysis in incident dialysis patients. Perit Dial Int 2009; 29: 182-190.
7. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27: 1341-1349.
8. Rea ME, Dunlap ME. Renal hemodynamics in heart failure: implications for treatment. Curr Opin Nephrol Hypertens 2008; 17: 87-92. (Pubitemid 350295203)
9. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010; 21: 1819-1834.
10. Wang X, Breaks J, Loutzenhiser K, Loutzenhiser R. Effects of inhibition of the Na +K +2Cl cotransporter on myogenic and angiotensin II responses of the rat afferent arteriole. Am J Physiol Renal Physiol 2007; 292: F999-F1006. (Pubitemid 46393426)
11. Bader M, Ganten D. Regulation of renin: new evidence from cultured cells and genetically modified mice. J Mol Med 2000; 78: 130-139. (Pubitemid 30337494)
12. Berl T. Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 2009; 10: 1-8.
13. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32: 865-879. (Pubitemid 30663097)
14. Ruster C, Wolf G. Renin-angiotensin-aldosterone system and progression of renal disease. J Am Soc Nephrol 2006; 17: 2985-2991. (Pubitemid 44707758)
15. Campbell RC, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol 2002; 13(Suppl 3): S190-S195. (Pubitemid 35216024)
16. Hollenberg NK. Direct renin inhibition and the kidney. Nat Rev Nephrol 2010; 6: 49-55.
17. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Smith B, Weissbach N, Maboudian M, Botha J, van Ingen H. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-425.
18. Muller DN, Klanke B, Feldt S, Cordasic N, Hartner A, Schmieder RE, Luft FC, Hilgers KF. (Pro)renin receptor peptide inhibitor 'handle-region' peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008; 51: 676-681. (Pubitemid 351301520)
19. Armenia A, Sattar MA, Abdullah NA, Khan MA, Johns EJ. Functional subtypes of renal alpha1-adrenoceptor in diabetic and non-diabetic 2K1C Goldblatt renovascular hypertension. Acta Pharmacol Sin 2008; 29: 564-572. (Pubitemid 351601450)
20. Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H, Kim-Mitsuyama S. Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 2010; 53: 180-191.
21. Ino J, Kojima C, Osaka M, Nitta K, Yoshida M. Dynamic observation of mechanicallyinjured mouse femoral artery reveals an antiinflammatory effect of renin inhibitor. Arterioscler Thromb Vasc Biol 2009; 29: 1858-1863.
22. Buñag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 1973; 34: 279-282.
23. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1996; 27: 176-183. (Pubitemid 26045914)
24. Vikse BE, Bostad L, Aasarød K, Lysebo DE, Iversen BM. Prognostic factors in mesangioproliferative glomerulonephritis. Nephrol Dial Transplant 2002; 17: 1603-1613. (Pubitemid 35012162)
25. Shanley PF. The pathology of chronic renal ischemia. Semin Nephrol 1996; 16: 21-32. (Pubitemid 26030828)
26. Kellerman PS. Cellular and metabolic consequences of chronic ischemia on kidney function. Semin Nephrol 1996; 16: 33-42. (Pubitemid 26030829)
27. el-Dahr SS, Dipp S, Guan S, Navar LG. Renin, angiotensinogen, and kallikrein gene expression in two-kidney Goldblatt hypertensive rats. Am J Hypertens 1993; 6: 914-919. (Pubitemid 23363178)
28. Krebs C, Hamming I, Sadaghiani S, Steinmetz OM, Meyer-Schwesinger C, Fehr S, Stahl RA, Garrelds IM, Danser AH, van Goor H, Contrepas A, Nguyen G, Wenzel U. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int 2007; 72: 725-730. (Pubitemid 47373792)
29. Danser AH. Prorenin receptors: are they biologically relevant? Curr Opin Nephrol Hypertens 2009; 18: 74-78.
30. Feldman DL, Jin L, Xuan H, Contrepas A, Zhou Y, Webb RL, Mueller DN, Feldt S, Cumin F, Maniara W, Persohn E, Schuetz H, Jan Danser AH, Nguyen G. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-136.
31. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390: 45-51. (Pubitemid 27494749)
32. Wang Y, Sun Z. Current understanding of klotho. Ageing Res Rev 2009; 8: 43-51.
33. Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K, Kishimoto T, Kinoshita S, Kuroki T, Nabeshima Y. Severely reduced production of klotho in human chronic renal failure kidney. Biochem Biophys Res Commun 2001; 280: 1015-1020. (Pubitemid 32924441)
34. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Mü ller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-576. (Pubitemid 41376839)
35. Schmerbach K, Pfab T, Zhao Y, Culman J, Mueller S, Villringer A, Muller DN, Hocher B, Unger T, Thoene-Reineke C. Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes. PLoS One 2010; 5: e15052.
36. Dong YF, Liu L, Lai ZF, Yamamoto E, Kataoka K, Nakamura T, Fukuda M, Tokutomi Y, Nako H, Ogawa H, Kim-Mitsuyama S. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. J Hypertens 2010; 28: 1554-1565.
37. Gross O, Girgert R, Rubel D, Temme J, Theissen S, Mü ller GA. Renal protective effects of aliskiren beyond its antihypertensive property in a mouse model of progressive fibrosis. Am J Hypertens 2011; 24: 355-361.